BioNTech SE Net Assets
BioNTech SE net assets. Based on the latest financial reports, BioNTech SE (22UA) has net assets worth €18.70 Billion EUR (≈ $21.86 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€21.07 Billion ≈ $24.64 Billion USD) and total liabilities (€2.38 Billion ≈ $2.78 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore BioNTech SE (22UA) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €18.70 Billion |
| % of Total Assets | 88.72% |
| Annual Growth Rate | 103.7% |
| 5-Year Change | 61.63% |
| 10-Year Change | N/A |
| Growth Volatility | 275.27 |
Net Assets of BioNTech SE (2016–2025)
Net assets of BioNTech SE from 2016 to 2025. This chart illustrates how BioNTech SE's net assets have evolved over time, based on quarterly financial data. See BioNTech SE (22UA) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for BioNTech SE (2016–2025)
The table below shows the annual net assets of BioNTech SE from 2016 to 2025. For live market cap and overall valuation, see how much is BioNTech SE worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €19.22 Billion ≈ $22.48 Billion |
-0.96% |
| 2024-12-31 | €19.41 Billion ≈ $22.69 Billion |
-4.12% |
| 2023-12-31 | €20.25 Billion ≈ $23.67 Billion |
+0.95% |
| 2022-12-31 | €20.06 Billion ≈ $23.45 Billion |
+68.62% |
| 2021-12-31 | €11.89 Billion ≈ $13.90 Billion |
+766.99% |
| 2020-12-31 | €1.37 Billion ≈ $1.60 Billion |
+177.99% |
| 2019-12-31 | €493.49 Million ≈ $576.94 Million |
+84.83% |
| 2018-12-31 | €267.00 Million ≈ $312.15 Million |
+653.87% |
| 2017-12-31 | €-48.21 Million ≈ $-56.36 Million |
-251.32% |
| 2016-12-31 | €31.86 Million ≈ $37.25 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to BioNTech SE's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1807400000000.0% over the analyzed period, indicating profitable operations and earnings retention.
BioNTech SE Net Assets Breakdown (December 2025)
BioNTech SE net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €17.96 Billion | 93.43% |
| Other Components | €1.26 Billion | 6.57% |
| Total Equity | €19.22 Billion | 100.00% |
BioNTech SE Competitors by Market Cap
The table below lists competitors of BioNTech SE ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
China United Network Communications Ltd
SHG:600050
|
$20.08 Billion |
|
Canon Inc
F:CNNA
|
$20.09 Billion |
|
First Financial Holding Co Ltd
TW:2892
|
$20.14 Billion |
|
CHINA SHENHUA EN.A ADR/4
F:IKFC
|
$20.14 Billion |
|
China Development Financial Holding Corp
TW:2883
|
$20.02 Billion |
|
Fidelity National Information Services Inc
NYSE:FIS
|
$19.96 Billion |
|
CLP HLDGS LTD ADR/1 HD 5
F:CLP1
|
$19.96 Billion |
|
Yihai Kerry Arawana Holdings Co Ltd
SHE:300999
|
$19.94 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioNTech SE's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 19,411,100,000 to 19,224,200,000, a change of -186,900,000 (-1.0%).
- Net loss of 1,136,100,000 reduced equity.
- Other factors increased equity by 949,200,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-1.14 Billion | -5.91% |
| Other Changes | €949.20 Million | +4.94% |
| Total Change | €- | -0.96% |
Book Value vs Market Value Analysis
This analysis compares BioNTech SE's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.02x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €-0.21 | €77.90 | x |
| 2018-12-31 | €1.16 | €77.90 | x |
| 2019-12-31 | €2.18 | €77.90 | x |
| 2020-12-31 | €5.68 | €77.90 | x |
| 2021-12-31 | €49.04 | €77.90 | x |
| 2022-12-31 | €82.46 | €77.90 | x |
| 2023-12-31 | €85.16 | €77.90 | x |
| 2024-12-31 | €80.89 | €77.90 | x |
| 2025-12-31 | €76.49 | €77.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioNTech SE utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.91%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -39.59%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 1.14x
- Recent ROE (-5.91%) is below the historical average (8.40%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -139.05% | 0.16x | 0.00x | €-80.72 Million |
| 2018 | -18.04% | -37.64% | 0.20x | 2.45x | €-74.63 Million |
| 2019 | -36.28% | -164.89% | 0.14x | 1.62x | €-228.41 Million |
| 2020 | 1.11% | 3.15% | 0.21x | 1.69x | €-121.99 Million |
| 2021 | 86.54% | 54.24% | 1.20x | 1.33x | €9.10 Billion |
| 2022 | 47.04% | 54.50% | 0.74x | 1.16x | €7.43 Billion |
| 2023 | 4.60% | 24.36% | 0.17x | 1.14x | €-1.09 Billion |
| 2024 | -3.43% | -24.18% | 0.12x | 1.16x | €-2.61 Billion |
| 2025 | -5.91% | -39.59% | 0.13x | 1.14x | €-3.06 Billion |
Industry Comparison
This section compares BioNTech SE's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $380,407,590
- Average return on equity (ROE) among peers: -34.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioNTech SE (22UA) | €18.70 Billion | 0.00% | 0.13x | $20.05 Billion |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $-1.58 Million | 0.00% | 0.00x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $19.57 Million | -78.67% | 0.35x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $243.06 Million | -74.97% | 0.23x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $144.67 Million |
| PreveCeutical Medical Inc (18H) | $-6.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $2.53 Billion | -16.11% | 0.12x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $696.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic tr… Read more